CervoMed Q1 EPS Increased by Brookline Capital Management

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Management upped their Q1 2025 EPS estimates for CervoMed in a research report issued to clients and investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.48). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.

Several other research analysts have also recently issued reports on the stock. Chardan Capital raised shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a report on Thursday, March 13th. Roth Capital raised shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Canaccord Genuity Group increased their target price on shares of CervoMed from $12.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Roth Mkm increased their target price on shares of CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Price Performance

NASDAQ CRVO opened at $9.37 on Thursday. CervoMed has a 52-week low of $1.80 and a 52-week high of $26.38. The firm has a 50-day moving average price of $2.87 and a 200 day moving average price of $7.88.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The firm had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Hedge Funds Weigh In On CervoMed

A number of hedge funds have recently made changes to their positions in the business. Citizens Financial Group Inc. RI raised its stake in shares of CervoMed by 13.2% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after acquiring an additional 3,553 shares during the period. FMR LLC purchased a new position in shares of CervoMed in the 3rd quarter valued at $56,000. Barclays PLC raised its stake in shares of CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after acquiring an additional 5,919 shares during the period. JPMorgan Chase & Co. raised its stake in shares of CervoMed by 251.8% in the 4th quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock valued at $34,000 after acquiring an additional 10,352 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of CervoMed in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.